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Objective: Apo2L/tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL) is a potential anticancer drug that promotes apoptosis specifically in tumor
cells. Because not all cancer cells are susceptible to Apo2L/TRAIL, the aim of our
study was to determine whether non–small cell lung cancer cells can be sensitized
by chemotherapeutic agents for Apo2L/TRAIL-induced apoptosis. In addition,
endogenous expression levels of the caspase-inhibiting cellular protease caspase-8
inhibitory protein (C-FLIP) were measured to investigate partial resistance to
Apo2L/TRAIL.
Methods: Six human lung cancer cell lines (A549, NCI-H358, Calu1, Calu6,
SkMes1, and SkLu1) were incubated with soluble Apo2L/TRAIL and two different
concentrations each of cisplatin, paclitaxel, doxorubicin, 5-fluorouracil, and camp-
tothecin. After 24 hours the rate of apoptosis was measured by annexin V/propid-
ium iodide staining followed by FACScan analysis. Expression levels of C-FLIP in
cell lines and lung cancer biopsy specimens were determined by Western blotting.
Results: Treatment of lung cancer cells with Apo2L/TRAIL alone resulted in apop-
totic cell death in four cell lines (P < .001). Combining Apo2L/TRAIL and
chemotherapeutic agents enhanced the rate of apoptosis significantly. Statistical
analysis revealed a synergistic effect of Apo2L/TRAIL in combination with 1.8
mmol/L camptothecin and 100 µmol/L cisplatin, each in four of the six cell lines (P
< .002). Western blot analysis showed that sensitization to Apo2L/TRAIL did not
correlate with the expression of cellular protease caspase-8 inhibitory protein.
Furthermore, no increased cellular protease caspase-8 inhibitory protein levels rel-
ative to those in normal lung tissue could be found in non–small cell lung cancer
specimens from 12 patients.
Conclusion: Apo2L/TRAIL-induced apoptosis in non–small cell lung cancer cell
lines is significantly enhanced by chemotherapeutic agents. Resistance and sensiti-
zation to Apo2L/TRAIL are not correlated with the endogenous expression level of
cellular protease caspase-8 inhibitory protein, implying that in non–small cell lung
cancer other mechanisms are responsible for inhibition of the Apo2L/TRAIL path-
way. Even though the molecular mechanism remains unclear, the combination of
Apo2L/TRAIL with chemotherapy may be a promising treatment modality for
non–small cell lung cancer.
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Lung cancer is the leading cause of cancerdeaths in the United States among both menand women. The projected number of newcases of lung cancer in 1999 in the UnitedStates is 171,600, with more than 158,000people dying from the disease during the
same year. In fact, more people die each year of lung can-
cer than of breast, colorectal, prostate, and ovarian malig-
nancies combined.1
Eighty percent of all newly diagnosed lung cancers are
non–small cell lung cancer (NSCLC). Current protocols for
therapy of NSCLC include surgery, radiotherapy, and
chemotherapy.2 The aim of the latter two treatment modali-
ties is the induction of apoptosis in cancer cells. Apoptosis
is a morphologically distinct form of cell death that is asso-
ciated with chromatin condensation and membrane bleb-
bing. This type of cell death can be induced by cytokines of
the tumor necrosis factor (TNF) family. A recently cloned
member of this family is Apo2L/TNF-related apoptosis-
inducing ligand (TRAIL).3 This cytokine, in contrast to
other members of the TNF family, seems to induce apopto-
sis only in cancer cells and not in normal tissue.4,5 It thus
could provide new therapeutic options for NSCLC.
The first aim of this study was to confirm that
Apo2L/TRAIL does induce apoptosis in NSCLC cell lines.
The second aim was to investigate whether this mechanism
could be augmented by chemotherapeutic agents. The final
aim was to evaluate the current hypothesis on the role of cellu-
lar protease caspase-8 inhibitory protein (c-FLIP) in resistance
to Apo2L/TRAIL-induced apoptosis in NSCLC cell lines.
Material and Methods
Reagents
Soluble, nontrimerized Apo2L/TRAIL produced in Escherichia coli
was kindly provided by Genentech, Inc, South San Francisco, Calif.
Cisplatin, propidium iodide, cycloheximide (INN: cicloheximide),
Bradford reagent, and the secondary goat antimouse and the mono-
clonal anti α-tubulin antibodies were purchased from Sigma
Chemical Co, St Louis, Missouri. The 5-fluorouracil was from F.
Hoffmann-La Roche Ltd, Basel, Switzerland. The protease inhibitor
cocktail was produced by Roche Diagnostics GmbH, Mannheim,
Germany. Paclitaxel, doxorubicin, camptothecin, and annexin V
conjugated with fluorescein isothiocyanate were obtained from
Alexis Corporation, San Diego, California. The monoclonal anti–c-
FLIP (clone NF6) antibody was a kind gift from the group of Peter
Krammer (German Cancer Research Center, Heidelberg, Germany).
Culture media, penicillin, and streptomycin were purchased from
Life Technologies Ltd, Paisley, United Kingdom. Fetal calf serum
was purchased from Biochrom (Berlin, Germany). The reagents for
enhanced chemoluminescence were obtained from Amersham
Pharmacia plc, Little Chalfont, United Kingdom.
Tumor Cell Lines and Cell Culture
The human NSCLC cell lines (A549, nonspecified lung carci-
noma; NCI-H358, bronchoalveolar carcinoma; Calu1, epidermoid
lung carcinoma; Calu6, anaplastic lung carcinoma; SkMes1, squa-
mous cell carcinoma, and SkLu1, adenocarcinoma; American
Type Culture Collection, Manassas, Va) were cultured at 37°C
under 5% carbon dioxide in Dulbecco’s modified Eagle medium
supplemented with 10% fetal calf serum and antibiotics.
Annexin V/Propidium Iodide Staining
Cells were plated at 5 × 104 cells/well in 24-well plates and
allowed to attach overnight. Apo2L/TRAIL and chemotherapeutic
agents were added at the indicated concentrations. After 24 hours
cells were harvested by trypsinization, centrifuged, and resus-
pended in 50 µL of annexin V in binding buffer (10-mmol/L N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid, pH 7.4;
150-mmol/L sodium chloride, 5-mmol/L potassium chloride; 1-
mmol/L magnesium chloride; and 1.8-mmol/L calcium chloride).
After 10 minutes of incubation at 4°C, 150 µL of annexin V bind-
ing buffer and 20 µL of propidium iodide (100 µg/mL in phos-
phate-buffered saline solution) were added, and flow cytometry
(FACScan; BD Immunocytometry Systems, San Jose, Calif) was
performed. For every experiment a minimum of 1 × 104 cells were
analyzed. All experiments were performed in triplicate (n = 3).
Western Blot
Cells were harvested and then lysed for 30 minutes on ice in a buffer
containing 20-mmol/L N-2-hydroxyethylpiperazine-N-2-ethanesul-
fonic acid, pH 7.6, 120-mmol/L sodium chloride; 0.2-mmol/L eth-
ylenediaminetetraacetic acid; 1% Triton X-100 (Sigma Chemical
Co, St Louis, Mo), and protease inhibitors. Lysates were centrifuged
at 14,000 rpm for 15 minutes and supernatants were collected.
Protein concentration was determined with Bradford reagent by
measuring the extinction at 595 nm and using bovine serum albumin
dissolved in lysis buffer as a standard. Proteins were separated by
denaturating gel electrophoresis with 12% polyacrylamide and load-
ing the same amount of protein on every lane. The proteins were
transferred to nitrocellulose membranes and incubated with
blocking buffer (20-mmol/L tris[hydroxymethyl]aminomethane
hydrochloride, pH 7.5, 500-mmol/L sodium chloride, 0.05% Tween
20, and 5% milk powder). After washing with buffer containing 20-
mmol/L tris(hydroxymethyl)aminomethane hydrochloride, pH 7.5,
500-mmol/L sodium chloride, and 0.05% Tween 20, blots were
incubated with the primary antibodies diluted in blocking solution.
After a second washing the blots were incubated with horseradish
peroxidase-coupled secondary antibody, washed, and developed
with enhanced chemoluminescence reagent.
For stripping, membranes were incubated for 30 minutes at
50°C in a buffer containing 62.5-mmol/L tris(hydroxymethyl)
aminomethane hydrochloride, pH 6.7, 2% sodium dodecyl sulfate,
and 100-mmol/L β-mercaptoethanol. The blots were then washed
and blocked again.
Statistical Analysis
For determination of synergy a statistical analysis was performed.
For parameter estimates, t tests were calculated in a logistic regres-
sion model (quasilikelihood approach according to McCullagh
and Nelder6). The statistical software S-PLUS 2000 (MathSoft
Engineering & Education, Inc, Cambridge, Mass) was used.
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Results
Apo2L/TRAIL in NSCLC Cell Lines
To determine susceptibility of NSCLC cell lines to
Apo2L/TRAIL, cells were treated with 1-mg/mL
Apo2L/TRAIL. For assessment of apoptosis, cells were
stained with annexin V/propidium iodide after 24 hours of
incubation. A cell line was considered susceptible to
Apo2L/TRAIL if more than 5% of the cells had positive
staining for annexin V/propidium iodide compared with
nontreated control cells. Four of six cell lines were suscep-
tible to Apo2L/TRAIL-induced apoptosis. The highest rate
of apoptotic cell death was noted in SkMes1 cells (33.2%),
followed by NCI-H358 cells (19%), Calu6 cells (12.4%),
and A549 cells (5.1%, P < .001, Figure 1, A).
Apo2L/TRAIL and Chemotherapeutic Agents
To investigate synergistic effects of Apo2L/TRAIL and
chemotherapeutic agents, cell lines were incubated for 24
hours with 100 ng/mL Apo2L/TRAIL in combination with
two different concentrations each of the chemotherapeutic
agents doxorubicin, 5-fluorouracil, camptothecin, cisplatin,
and paclitaxel. The doses of chemotherapeutic agents were
determined in preliminary experiments so that at least one
of the concentrations did not induce a high rate of apopto-
sis as a single treatment (data not shown). Apoptotic cell
death was measured by annexin V/propidium iodide stain-
ing followed by flow cytometry (Figure 2). Synergistic
effects could be determined with Apo2L/TRAIL and camp-
tothecin (1.8 mmol/L) and Apo2L/TRAIL and cisplatin
(100 µmol/L), each in four of the six cell lines (P < .002,
Table 1). Less pronounced effects were seen for the combi-
nation of Apo2L/TRAIL with doxorubicin and with 5-fluo-
rouracil, whereas paclitaxel did not show a synergistic
effect with Apo2L/TRAIL in any of the cell lines tested
(Table 1).
Susceptibility of the NSCLC Cell Lines to
Apo2L/TRAIL in Correlation With the Endogenous
Expression of c-FLIP
Figure 1, B, indicates that the level of c-FLIP expression
was not correlated with Apo2L/TRAIL-induced apoptosis.
NCI-H358, a cell line susceptible to Apo2L/TRAIL,
showed the highest expression of c-FLIP. Two other cell
lines, Calu1 and SkLu1, which are not sensitive to
Apo2L/TRAIL-induced apoptosis, clearly revealed less
expression of c-FLIP. Rehybridization of the blot with an
antitubulin antibody demonstrated comparable amounts of
protein loaded on each lane (Figure 1, B).
Apo2L/TRAIL and Chemotherapeutic Agents
Correlated With the Expression of c-FLIP
Because NSCLC cell lines can be sensitized to
Apo2L/TRAIL-induced apoptosis by chemotherapeutic
agents, we next evaluated whether this effect was inversely
correlated with the expression of c-FLIP. NCI-H358 cells
were treated with chemotherapeutic agents and then ana-
lyzed by Western blot for the expression of c-FLIP. Again,
no correlation was noted between Apo2L/TRAIL-induced
apoptosis and the expression of c-FLIP (Figure 3).
Cycloheximide, which downwardly regulates the expres-
sion of c-FLIP,7 was used in negative control runs.
Comparable loading of protein was demonstrated by rehy-
bridization with an antitubulin antibody (Figure 3).
Expression of c-FLIP in Primary NSCLC
In primary tumors of 6 patients with adenocarcinoma and 6
patients with squamous cell carcinoma, the expression of c-
FLIP was determined in comparison with normal lung tis-
sue. The results did not show a difference in the expression
of endogenous c-FLIP between normal lung tissue and
tumor (Figure 4).
Figure 1. Apo2L/TRAIL induces apoptosis in NSCLC cell lines, but
this is not correlated with expression of cFLIP. A, Cells were
treated with 1-mg/mL TRAIL/Apo2L for 24 hours, and apoptosis was
assessed by annexin V/propidium iodide staining followed by
FACScan analysis (n = 3). Bars represent mean; error bars repre-
sent SD. B, Expression of c-FLIP in NSCLC cell lines was deter-
mined by Western blot analysis. To confirm equal protein levels the
same blot was stripped and developed with antitubulin antibody.
A
B
Frese et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery • Volume 123, Number 1   171
G
TS
ET
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
Interestingly, when we used another antibody for deter-
mination of c-FLIP (polyclonal antibody catalog number
1161; ProSci Incorporated, Poway, Calif), we observed sig-
nificantly higher levels of this protein in the tumor than in
normal tissue. However, further control runs revealed that
this antibody was not specific (data not shown).
Discussion
Apo2L/TRAIL induced apoptosis in most of the NSCLC
cell lines studied. The combination of Apo2L/TRAIL with
chemotherapeutic agents increased apoptotic cell death in a
synergistic way.
Apoptosis may be induced by cytokines of the TNF fam-
ily, as for example TNF-α and Fas ligand (FasL). Binding of
TNF and FasL to their corresponding receptors on the cell
membrane leads to trimerization of a conserved cytoplasmic
receptor domain called death domain. Subsequently the
adapter molecule FADD/MORT1 and the protease caspase-
8 (FLICE) bind to the death receptor and form the death-
inducing signaling complex.8 Recruitment of caspase-8
Figure 2. Apo2L/TRAIL-induced apoptosis is augmented by chemotherapeutic agents. Cells were incubated for 24 hours
with 100ng/mL Apo2L/TRAIL (white bars), with chemotherapeutic agents (gray bars), and with combined Apo2L/TRAIL and
chemotherapy (black bars). Apoptosis was measured by annexin V/propidium iodide staining followed by flow cytometry
(n = 3). Bars represent mean; error bars represent SD. Concentrations of chemotherapeutic agents are indicated with num-
bers: 1 and 2, 0.5-mmol/L and 5-mmol/L doxorubicin; 3 and 4, 3-mmol/L and 30-mmol/L 5-fluorouracil; 5 and 6, 0.18-mmol/L
and 1.8-mmol/L camptothecin; 7 and 8, 10-µmol/L and 100-µmol/L cisplatin; 9 and 10, 10-nmol/L and 100-nmol/L paclitaxel.
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activates its proteolytic properties, which further initiates a
cascade of caspases and subsequent cleavage of death sub-
strates, finally leading to apoptosis.9,10 Systemically admin-
istered TNF-α and FasL induce acute toxic effects, such as
septic shock and acute hepatic failure, thereby limiting their
potential clinical use for the treatment of cancer.11,12
Another member of the TNF family, Apo2L/TRAIL, has
been cloned recently.3 Similar to TNF-α and FasL,
Apo2L/TRAIL induces apoptosis in various tumor cells but
not in normal cell lines.5 Furthermore, it has been demon-
strated that systemic administration of Apo2L/TRAIL in
SCID mice or nonhuman primates results in antitumoricidal
activity without any toxic effects on normal tissue.4
Recent studies, however, demonstrate that not all tumor
cell lines are susceptible to Apo2L/TRAIL-induced apopto-
sis. This was first thought to be due to the expression pat-
tern of the four distinct Apo2L/TRAIL receptors. Two of
Apo2L/TRAIL receptors (DcR1 and DcR2) lack a func-
tioning death domain and were initially believed to act as
“decoy” receptors. Subsequent studies could not confirm
this hypothesis.13
To overcome the resistance of some tumor cell lines to
Apo2L/TRAIL, two recently reported studies evaluated
synergistic action of Apo2L/TRAIL with chemotherapeutic
agents. Keane and colleagues14 demonstrated a synergistic
effect of Apo2L/TRAIL with doxorubicin and 5-fluo-
rouracil in breast cancer cell lines. Gliniak and Le15 noted
synergy of Apo2L/TRAIL with camptothecin but not with
other chemotherapeutic agents in colon carcinoma cell
lines. The data from our study confirm these findings by
showing a synergistic effect of camptothecin with
Apo2L/TRAIL in four of six NSCLC cell lines studied. In
addition, we noted synergy in four cell lines with the com-
bination of Apo2L/TRAIL and cisplatin, an agent com-
monly used for chemotherapy of NSCLC.
Interestingly, no synergistic effects have been observed
for the combination of paclitaxel and Apo2L/TRAIL.
Whereas all the other chemotherapeutic agents used in the
study are DNA-damaging agents, paclitaxel exerts its apop-
totic effects through stabilization of the microtubule system,
thus interfering with the cell cycle.16 Our data therefore
indicate that DNA damage, but not mitotic arrest, is needed
for Apo2L/TRAIL-induced apoptosis.
To date we do not have much information on systemic
toxicity of the combination of Apo2L/TRAIL with
chemotherapy. In the study performed in a mouse model by
Gliniak and Le,15 no toxic effect on normal tissue with the
combination of Apo2L/TRAIL and camptothecin was
observed. For possible clinical application, this point needs
further evaluation.
The question of why some tumor cells are susceptible to
Apo2L/TRAIL-induced apoptosis remains to be answered.
When the decoy receptor hypothesis could not be proved,
other groups suggested that resistance of some tumor cell
lines to Apo2L/TRAIL-induced apoptosis is related to the
expression of the intracellular antiapoptotic protein c-FLIP
(FLICE-inhibitory protein).17 c-FLIP was cloned as the cel-
lular homolog of a viral protein that was identified as an
inhibitor of apoptosis. It is structurally similar to caspase-8,
because it contains two death effector domains and a cas-
paselike domain, but it shows no caspase activity.18
To evaluate the role of c-FLIP in the resistance to
Apo2L/TRAIL in our NSCLC cell lines, endogenous
expression levels of c-FLIP were determined and compared
with the susceptibility to Apo2L/TRAIL. A correlation
between c-FLIP expression and susceptibility to
Apo2L/TRAIL could not be demonstrated. Similar data
have been demonstrated by Zhang and colleagues19 for
melanoma cell lines. We further compared the expression of
c-FLIP after treatment with chemotherapeutic agents with
the enhanced susceptibility to Apo2L/TRAIL after treat-
ment with chemotherapeutic agents. Again, there was no
correlation between endogenous c-FLIP and susceptibility
to Apo2L/TRAIL. Therefore, factors other than c-FLIP
TABLE 1. Augmentation of Apo2L/TRAIL toxicity by chemotherapy in NSCLC cell lines
NCI-H358 A549 Calu6 Calu1 SkMes1 SkLu1
TRAIL + 0.5-µmol/L doxorubicin – – – – + –
TRAIL + 5-µmol/L doxorubicin + – – – – +
TRAIL + 3-mmol/L 5-fluorouracil – + – – + –
TRAIL + 30-mmol/L 5-fluorouracil – + + – – –
TRAIL + 0.18-mmol/L camptothecin + – – – – +
TRAIL + 1.8-mmol/L camptothecin + + – + – +
TRAIL + 10-µmol/L cisplatin – – – – – –
TRAIL + 100-µmol/L cisplatin + – + – + +
TRAIL + 10-mmol/L paclitaxel – – – – – –
TRAIL + 100-mmol/L paclitaxel – – – – – –
Data represent the cell lines with and without significant augmentation of Apo2l/TRAIL-induced apoptosis by chemotherapeutic agents (P < .002).
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seem to be responsible for the resistance to Apo2L/TRAIL
induced apoptosis. In contrast, Leverkus and colleagues7
suggested an inhibition of the Apo2L/TRAIL pathway by
endogenous c-FLIP, as evidenced by experiments with
cycloheximide, an unspecific inhibitor of protein synthesis.
Treatment of cells with cycloheximide decreased levels of
c-FLIP and enhanced susceptibility to Apo2L/TRAIL, but
these findings were not confirmed with a specific inhibitor
of c-FLIP.
Our data also suggest that downward regulation of c-
FLIP, for example by an antisense approach, does not ren-
der NSCLC cell lines susceptible to Apo2L/TRAIL. This is
in contrast to the Fas (CD95) pathway, for which Nagaraju
and colleagues20 showed that downregulation of c-FLIP
enhances apoptotic cell death.
Other authors have reported that increased c-FLIP
expression blocks apoptosis and so mediates the escape of
tumors from the immune system by mediating resistance of
tumor cells to apoptosis.21,22 Our data demonstrate that lev-
els of c-FLIP in normal lung tissue and lung cancer tissue
are equal and therefore indicate that c-FLIP does not seem
to play a role in tumor immune escape in NSCLC.
In conclusion, Apo2L/TRAIL can efficiently induce
apoptosis in NSCLC cell lines. Furthermore, we have
shown for the first time that this effect can be augmented by
chemotherapeutic agents in NSCLC cell lines and that c-
FLIP does not modulate apoptotic cell death induced by
Apo2L/TRAIL. Combined therapy of Apo2L/TRAIL with
chemotherapeutic agents seems to be promising. Future in
vivo studies are needed to confirm these findings.
We thank Dr P.H. Krammer for the c-FLIP monoclonal anti-
body and Genentech Inc for providing Apo2L/TRAIL.
References
1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999.
CA Cancer J Clin. 1999;49:8-31, 1.
2. Johnson DH. Combined-modality therapy for unresectable, stage III
non-small-cell lung cancer—caveat emptor or caveat venditor? [edi-
torial] J Natl Cancer Inst. 1996;88:1175-7.
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK,
et al. Identification and characterization of a new member of the TNF
family that induces apoptosis. Immunity. 1995;3:673-82.
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA,
et al. Safety and antitumor activity of recombinant soluble Apo2 li-
gand. J Clin Invest. 1999;104:155-62.
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et
al. Tumoricidal activity of tumor necrosis factor-related apoptosis-
inducing ligand in vivo. Nat Med. 1999;5:157-63.
6. McCullagh P, Nelder JA. Generalized linear model. 2nd ed. Monographs
on statistics and applied probability. London; Chapman and Hall; 1989.
7. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB,
Krammer PH, et al. Regulation of tumor necrosis factor-related apop-
tosis-inducing ligand sensitivity in primary and transformed human
keratinocytes. Cancer Res. 2000;60:553-9.
8. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M,
Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-asso-
ciated proteins form a death-inducing signaling complex (DISC) with
the receptor. EMBO J. 1995;14:5579-88.
9. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-65.
10. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL
(APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58-66.
11. Havell EA, Fiers W, North RJ. The antitumor function of tumor necro-
sis factor (TNF). I. Therapeutic action of TNF against an established
murine sarcoma is indirect, immunologically dependent, and limited
by severe toxicity. J Exp Med. 1988;167:1067-85.
12. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A,
Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in
mice [published erratum appears in Nature 1993;365:568]. Nature.
1993;364:806-9.
13. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors
and control mechanisms. Curr Opin Immunol. 1998;10:559-63.
Figure 3. Augmentation of Apo2L/TRAIL-induced apoptosis does
not correlate with expression of c-FLIP. Cells were incubated with
5-mmol/L doxorubicin, 30-mmol/L 5-fluorouracil, 1.8-mmol/L
camptothecin, 100-µmol/L cisplatin, 100-nmol/L paclitaxel, and 1-
µg/mL cycloheximide for 24 hours. Expression of c-FLIP was
determined by Western blot. Equal amount of protein was shown
by reblotting against tubulin.
Figure 4. Expression of cFLIP in primary NSCLC (C) and normal
lung tissue (N). Protein lysates were obtained from frozen tissue
from patients who underwent lung resection. c-FLIP expression
was determined by Western blot. To confirm equal protein levels
the same blot was stripped and developed with antitubulin anti-
body. A, Adenocarcinoma; B, squamous cell carcinoma.
A
B
174 The Journal of Thoracic and Cardiovascular Surgery • January 2002
General Thoracic Surgery Frese et al
ED
ITO
RIA
L
CH
D
G
TS
A
CD
ET
CSP
G
TS
14. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S.
Chemotherapy augments TRAIL-induced apoptosis in breast cell
lines. Cancer Res. 1999;59:734-41.
15. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing li-
gand’s antitumor activity in vivo is enhanced by the chemotherapeu-
tic agent CPT-11. Cancer Res. 1999;59:6153-8.
16. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and
reality (a critical review). Int J Cancer. 1999;83:151-6.
17. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med.
1999;5:146-7.
18. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V,
et al. Inhibition of death receptor signals by cellular FLIP. Nature.
1997;388:190-5.
19. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation
of TNF-related apoptosis-inducing ligand (TRAIL) receptor and
FLICE-inhibitory protein expression to TRAIL-induced apoptosis of
melanoma. Cancer Res. 1999;59:2747-53.
20. Nagaraju K, Casciola-Rosen L, Rosen A, Thompson C, Loeffler L,
Parker T, et al. The inhibition of apoptosis in myositis and in normal
muscle cells. J Immunol. 2000;164:5459-65.
21. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune
escape of tumors in vivo by expression of cellular FLICE-inhibitory
protein. J Exp Med. 1999;190:1033-8.
22. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A.
The inhibitor of death receptor signaling, FLICE-inhibitory protein
defines a new class of tumor progression factors. J Exp Med.
1999;190:1025-32.
Discussion
Stephen G. Swisher, MD (Houston, Tex). Did you look at cas-
pase-8 cleavage in your cells that were resistant? If you saw cleav-
age of caspase-8, then you would know that the inhibition is
downstream from caspase-8, but if you do not see cleavage of cas-
pase-8, most likely there is a block up higher near the receptor,
maybe decoy receptors.
Dr Frese. Unfortunately, so far we have not looked at the
cleavage of caspase-8. At the moment we are waiting for a cas-
pase-8 antibody from the German Cancer Research Center.
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